Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab versus omalizumab for severe dual-phenotype asthma
ACTRN12618000850279Phase 4Completed
- Sponsor
- Peter Wark
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 4, open-label trial of mepolizumab and omalizumab in severe asthma (2 arms), sponsored by Peter Wark. Primary endpoint: Asthma Control Questionnaire-5 adjusted for baseline. Started Nov 2018; status: completed.
02
Drugs
mepolizumabomalizumab
03
Conditions
severe asthma
Beyond the preview
Go deeper on ACTRN12618000850279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000850279.